Literature DB >> 24662931

Development of broadly neutralizing antibodies from autologous neutralizing antibody responses in HIV infection.

Cynthia A Derdeyn1, Penny L Moore, Lynn Morris.   

Abstract

PURPOSE OF REVIEW: Detailed genetic and structural characterization has revealed that broadly neutralizing antibodies (bnAbs) against HIV-1 have unusually high levels of somatic hypermutation, long CDRH3 domains, and the ability to target one of four sites of vulnerability on the HIV-1 envelope (Env) glycoproteins. A current priority is to understand how bnAbs are generated during natural infection, and translate this information into immunogens that can elicit bnAb following vaccination. RECENT
FINDINGS: Strain-specific neutralizing antibodies can acquire broad neutralizing capacity when the transmitted/founder Env or a specific Env variant is recognized by an unmutated rearranged germline that has the capacity to develop bnAb-like features. This event could be relatively infrequent, as only certain germlines appear to possess inherent features needed for bnAb activity. Furthermore, the glycosylation pattern and diversity of circulating HIV-1 Envs, as well as the state of the B-cell compartment, may influence the activation and maturation of certain antibody lineages.
SUMMARY: Collectively, studies over the last year have suggested that the development of HIV-1 Env immunogens that bind and activate bnAb-like germlines is feasible. However, more information about the features of Env variants and the host factors that lead to breadth during natural infection are needed to elicit bnAbs through immunization.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24662931      PMCID: PMC4068799          DOI: 10.1097/COH.0000000000000057

Source DB:  PubMed          Journal:  Curr Opin HIV AIDS        ISSN: 1746-630X            Impact factor:   4.283


  57 in total

1.  Infection by discordant strains of HIV-1 markedly enhances the neutralizing antibody response against heterologous virus.

Authors:  Rebecca L R Powell; Thompson Kinge; Phillipe N Nyambi
Journal:  J Virol       Date:  2010-07-14       Impact factor: 5.103

2.  The B cell response is redundant and highly focused on V1V2 during early subtype C infection in a Zambian seroconverter.

Authors:  Rebecca M Lynch; Rong Rong; Saikat Boliar; Anurag Sethi; Bing Li; Joseph Mulenga; Susan Allen; James E Robinson; S Gnanakaran; Cynthia A Derdeyn
Journal:  J Virol       Date:  2010-10-27       Impact factor: 5.103

3.  Genetic characteristics of HIV-1 subtype C envelopes inducing cross-neutralizing antibodies.

Authors:  Cecilia Rademeyer; Penny L Moore; Natasha Taylor; Darren P Martin; Isaac A Choge; Elin S Gray; Haynes W Sheppard; Clive Gray; Lynn Morris; Carolyn Williamson
Journal:  Virology       Date:  2007-07-16       Impact factor: 3.616

4.  Evolution of broadly cross-reactive HIV-1-neutralizing activity: therapy-associated decline, positive association with detectable viremia, and partial restoration of B-cell subpopulations.

Authors:  Carolina B Ferreira; Alberto Merino-Mansilla; Anuska Llano; Ignacio Pérez; Isabel Crespo; Laia Llinas; Felipe Garcia; Jose M Gatell; Eloisa Yuste; Victor Sanchez-Merino
Journal:  J Virol       Date:  2013-09-04       Impact factor: 5.103

5.  Potent and broad neutralization of HIV-1 subtype C by plasma antibodies targeting a quaternary epitope including residues in the V2 loop.

Authors:  Penny L Moore; Elin S Gray; Daniel Sheward; Maphuti Madiga; Nthabeleng Ranchobe; Zhong Lai; William J Honnen; Molati Nonyane; Nancy Tumba; Tandile Hermanus; Sengeziwe Sibeko; Koleka Mlisana; Salim S Abdool Karim; Carolyn Williamson; Abraham Pinter; Lynn Morris
Journal:  J Virol       Date:  2011-01-26       Impact factor: 5.103

6.  Isolation of a monoclonal antibody that targets the alpha-2 helix of gp120 and represents the initial autologous neutralizing-antibody response in an HIV-1 subtype C-infected individual.

Authors:  Elin S Gray; M Anthony Moody; Constantinos Kurt Wibmer; Xi Chen; Dawn Marshall; Joshua Amos; Penny L Moore; Andrew Foulger; Jae-Sung Yu; Bronwen Lambson; Salim Abdool Karim; John Whitesides; Georgia D Tomaras; Barton F Haynes; Lynn Morris; Hua-Xin Liao
Journal:  J Virol       Date:  2011-05-25       Impact factor: 5.103

7.  The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection.

Authors:  Elin S Gray; Maphuti C Madiga; Tandile Hermanus; Penny L Moore; Constantinos Kurt Wibmer; Nancy L Tumba; Lise Werner; Koleka Mlisana; Sengeziwe Sibeko; Carolyn Williamson; Salim S Abdool Karim; Lynn Morris
Journal:  J Virol       Date:  2011-03-09       Impact factor: 5.103

8.  Characteristics of the earliest cross-neutralizing antibody response to HIV-1.

Authors:  Iliyana Mikell; D Noah Sather; Spyros A Kalams; Marcus Altfeld; Galit Alter; Leonidas Stamatatos
Journal:  PLoS Pathog       Date:  2011-01-13       Impact factor: 6.823

9.  Limited neutralizing antibody specificities drive neutralization escape in early HIV-1 subtype C infection.

Authors:  Penny L Moore; Nthabeleng Ranchobe; Bronwen E Lambson; Elin S Gray; Eleanor Cave; Melissa-Rose Abrahams; Gama Bandawe; Koleka Mlisana; Salim S Abdool Karim; Carolyn Williamson; Lynn Morris
Journal:  PLoS Pathog       Date:  2009-09-18       Impact factor: 6.823

10.  Escape from autologous neutralizing antibodies in acute/early subtype C HIV-1 infection requires multiple pathways.

Authors:  Rong Rong; Bing Li; Rebecca M Lynch; Richard E Haaland; Megan K Murphy; Joseph Mulenga; Susan A Allen; Abraham Pinter; George M Shaw; Eric Hunter; James E Robinson; S Gnanakaran; Cynthia A Derdeyn
Journal:  PLoS Pathog       Date:  2009-09-18       Impact factor: 6.823

View more
  50 in total

Review 1.  A Shot in the Arm for HIV Prevention? Recent Successes and Critical Thresholds.

Authors:  Thomas J Hope; Jeanne M Marrazzo
Journal:  AIDS Res Hum Retroviruses       Date:  2015-11       Impact factor: 2.205

2.  Honing a harder-hitting hammerhead improves broadly neutralizing antibody breadth and potency.

Authors:  George K Lewis
Journal:  J Clin Invest       Date:  2015-05-18       Impact factor: 14.808

3.  Effects of partially dismantling the CD4 binding site glycan fence of HIV-1 Envelope glycoprotein trimers on neutralizing antibody induction.

Authors:  Ema T Crooks; Keiko Osawa; Tommy Tong; Samantha L Grimley; Yang D Dai; Robert G Whalen; Daniel W Kulp; Sergey Menis; William R Schief; James M Binley
Journal:  Virology       Date:  2017-03-06       Impact factor: 3.616

4.  Envelope characteristics in individuals who developed neutralizing antibodies targeting different epitopes in HIV-1 subtype C infection.

Authors:  Bongiwe Ndlovu; Kamini Gounder; Daniel Muema; Nagarajan Raju; Tandile Hermanus; Qiniso Mthethwa; Kim Robertson; Bruce D Walker; Ivelin S Georgiev; Lynn Morris; Penny L Moore; Thumbi Ndung'u
Journal:  Virology       Date:  2020-03-25       Impact factor: 3.616

5.  Exploration of broadly neutralizing antibody fragments produced in bacteria for the control of HIV.

Authors:  Sarah B Lloyd; Keith P Niven; Ben R Kiefel; David C Montefiori; Arnold Reynaldi; Miles P Davenport; Stephen J Kent; Wendy R Winnall
Journal:  Hum Vaccin Immunother       Date:  2017-09-26       Impact factor: 3.452

6.  Strain-Specific V3 and CD4 Binding Site Autologous HIV-1 Neutralizing Antibodies Select Neutralization-Resistant Viruses.

Authors:  M Anthony Moody; Feng Gao; Thaddeus C Gurley; Joshua D Amos; Amit Kumar; Bhavna Hora; Dawn J Marshall; John F Whitesides; Shi-Mao Xia; Robert Parks; Krissey E Lloyd; Kwan-Ki Hwang; Xiaozhi Lu; Mattia Bonsignori; Andrés Finzi; Nathan A Vandergrift; S Munir Alam; Guido Ferrari; Xiaoying Shen; Georgia D Tomaras; Gift Kamanga; Myron S Cohen; Noel E Sam; Saidi Kapiga; Elin S Gray; Nancy L Tumba; Lynn Morris; Susan Zolla-Pazner; Miroslaw K Gorny; John R Mascola; Beatrice H Hahn; George M Shaw; Joseph G Sodroski; Hua-Xin Liao; David C Montefiori; Peter T Hraber; Bette T Korber; Barton F Haynes
Journal:  Cell Host Microbe       Date:  2015-09-09       Impact factor: 21.023

7.  Coexistence of potent HIV-1 broadly neutralizing antibodies and antibody-sensitive viruses in a viremic controller.

Authors:  Natalia T Freund; Haoqing Wang; Louise Scharf; Lilian Nogueira; Joshua A Horwitz; Yotam Bar-On; Jovana Golijanin; Stuart A Sievers; Devin Sok; Hui Cai; Julio C Cesar Lorenzi; Ariel Halper-Stromberg; Ildiko Toth; Alicja Piechocka-Trocha; Harry B Gristick; Marit J van Gils; Rogier W Sanders; Lai-Xi Wang; Michael S Seaman; Dennis R Burton; Anna Gazumyan; Bruce D Walker; Anthony P West; Pamela J Bjorkman; Michel C Nussenzweig
Journal:  Sci Transl Med       Date:  2017-01-18       Impact factor: 17.956

Review 8.  Approaches to the induction of HIV broadly neutralizing antibodies.

Authors:  Penny L Moore; Carolyn Williamson
Journal:  Curr Opin HIV AIDS       Date:  2016-11       Impact factor: 4.283

9.  Determinants of HIV-1 broadly neutralizing antibody induction.

Authors:  Peter Rusert; Roger D Kouyos; Claus Kadelka; Hanna Ebner; Merle Schanz; Michael Huber; Dominique L Braun; Nathanael Hozé; Alexandra Scherrer; Carsten Magnus; Jacqueline Weber; Therese Uhr; Valentina Cippa; Christian W Thorball; Herbert Kuster; Matthias Cavassini; Enos Bernasconi; Matthias Hoffmann; Alexandra Calmy; Manuel Battegay; Andri Rauch; Sabine Yerly; Vincent Aubert; Thomas Klimkait; Jürg Böni; Jacques Fellay; Roland R Regoes; Huldrych F Günthard; Alexandra Trkola
Journal:  Nat Med       Date:  2016-09-26       Impact factor: 53.440

Review 10.  Strategies to guide the antibody affinity maturation process.

Authors:  Nicole A Doria-Rose; M Gordon Joyce
Journal:  Curr Opin Virol       Date:  2015-04-24       Impact factor: 7.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.